An FDA memo reaffirmed the efficacy of a gout drug treatment developed by Savient Pharmaceutical Inc. (Nasdaq: SVNT), but identified other risks to patients. The stock price leaped $3.33 to close at $9.26.
FDA Affirms Efficacy Of Savient's Gout Treatment
June 12, 2009 at 17:37 PM EDT
